Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
BACKGROUND: Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. METHODS: After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. RESULTS: The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. CONCLUSIONS: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Clinical Infectious Diseases
- Topic
- Antifungal resistance and susceptibility
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Janssen PharmaceuticalsNational Institute of Allergy and Infectious DiseasesEuropean Organisation for Research and Treatment of CancerMedical Research CouncilEuropean CommissionUniversity at BuffaloNational Institutes of HealthBasilea PharmaceuticaAstellas PharmaItalfarmacoWellcome TrustUniversity of Texas Health Science Center at San AntonioGlaxoSmithKlineCentre Hospitalier Universitaire VaudoisUniversity of AberdeenUniversity of PennsylvaniaWayne State UniversityNational Health and Medical Research CouncilChildren's Hospital of PhiladelphiaDaiichi Sankyo EuropeGilead SciencesUCB PharmaValeant Pharmaceuticals InternationalSanofiAmgenMedical School, University of MichiganPfizer
- Keywords
- MedicineDiseaseEpidemiologyCancerIntensive care medicineFamily medicinePathologyInternal medicine
- Has abstract in OpenAlex
- yes